Akka Venture

Akka Venture is a Paris-based growth advisory firm that specializes in providing strategic and financial services to European companies and their investors. The firm focuses on helping growth companies by offering a range of services, including fundraising, growth advisory, investor services, and mergers and acquisitions. By leveraging its expertise, Akka Venture aims to enable clients to identify business opportunities and achieve sustainable growth.

David Jouarisse

Founder and Managing Partner

2 past transactions

Innate Pharma

Series C in 2004
Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.

Innate Pharma

Series B in 2002
Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.